Deficiency of Cathelicidin-related Antimicrobial Peptide Promotes Skin Papillomatosis in Mus musculus Papillomavirus 1-infected Mice

Sonja DORFER1, Katharina STRASSER1, Siegfried REIPERT2, Michael B. FISCHER1, Saeed SHAFTI-KERAMAT1, Michael BONELLI1, Georg SCHROCKENFUCHS1, Wolfgang BAUER1, Stefanie KANCZ1, Lena MÜLLER1 and Alessandra HANDISURYA1

1Department of Dermatology, 2Department of Transfusion Medicine and *Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, and ©Core Facility Cell Imaging and Ultrastructure Research, University of Vienna, Vienna, Austria.

INVESTIGATIVE REPORT

Cathelicidins have been reported to inhibit human papillomavirus infection in vitro; however, nothing is known about their activity in vivo. In this study, experimental skin infection with Mus musculus papillomavirus 1 resulted in robust development of cutaneous papillomas in cyclosporine A-treated C57BL/6J mice deficient for the murine cathelicidin-related antimicrobial peptide (CRAMP), in contrast to wild-type controls. Analysis of the underlying mechanisms revealed moderate disruption of virion integrity and lack of interference with viral entry and intracellular trafficking by a synthetic CRAMP peptide. Differences in the immune response to Mus musculus papillomavirus 1 infection were observed between CRAMP-deficient and wild-type mice. These included a stronger reduction in CD4+ and CD8+ T-cell numbers in infected skin, and lack of Mus musculus papillomavirus 1-specific neutralizing antibodies in response to cyclosporine A in the absence of endogenous CRAMP. CRAMP has modest direct antipapillomaviral effects in vitro, but exerts protective functions against Mus musculus papillomavirus 1 skin infection and disease development in vivo, primarily by modulation of cellular and humoral immunity.

Key words: antimicrobial peptide; cathelicidin; CRAMP; MmuPV1; skin papilloma; antiviral mechanisms.

Accepted Dec 17, 2020; Epub ahead of print Dec 22, 2020
Acta Derm Venereol 2021; 101: adv00367.

Corr.: Alessandra Handisurya, Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18–20, AT-1090 Vienna, Austria. E-mail: alessandra.handisurya@meduniwien.ac.at

Cathelicidins, such as human LL-37 and the murine orthologue cathelicidin-related antimicrobial peptide (CRAMP), are endogenous host defence peptides with broad antimicrobial and immunomodulatory functions. They are produced by many different cells, including neutrophils, leukocytes, and epithelial cells, and are expressed in numerous tissues, such as skin, intestine, and bone marrow (1, 2). In healthy human skin, expression of LL-37 is constitutively low, but can be induced by inflammatory or infectious stimuli (3). LL-37 has also been detected in human papillomavirus-induced genital and skin warts (4). Besides their role in the innate and adaptive immune defence against bacterial and fungal infections, cathelicidins demonstrate direct effects in vitro against several viruses, such as respiratory syncytial- (RSV), influenza A- (IAV), varicella zoster- (VZV), herpes simplex- (HSV), and vaccinia viruses (VV), through disruption of virions, interference with virus-cell binding, and inhibition of viral replication (5–9). Furthermore, exogenous administration of cathelicidins protected against virus infection in vivo and/or reduced disease activity and viral replication, as shown for RSV and IAV (6, 10). In mice deficient for endogenous CRAMP (Cnlp-null or CRAMP-knock-out (KO) mice), which lacked expression in neutrophil granules and epidermal keratinocytes (11), RSV-, VV- or HSV-induced disease severities were more pronounced and viral loads higher compared with wild-type (WT) mice, which endogenously expressed CRAMP (7, 8, 10).

Papillomaviruses (PVs) are non-enveloped, double-stranded DNA viruses that target epithelia of humans and many vertebrate species for infection with high species-specificity. PV infections are mostly asymptomatic and transient, but can lead to development of benign papillomas (warts) of skin and mucosa in their respective host. Persistent infections with certain oncogenic high-risk mucosal human PVs are established causes of anogenital and oropharyngeal cancers in humans. To date, antiviral activity of cathelicidins against infection of epithelial cells with PV-derived pseudovirions (PsVs), which display properties similar to native, infectious virions, has been demonstrated in vitro (12). While this suggests a possible protective effect of cathelicidins against PV infections and associated diseases, in vivo investigations have not yet been performed.

SIGNIFICANCE

Cathelicidins are host defence (antimicrobial) peptides. This study demonstrates that mice, which lack the murine cathelicidin-related antimicrobial peptide in their skin and immune cells, consistently developed large papillomas on the skin after infection with a mouse papillomavirus and concomitant immunosuppression. In contrast, the presence of cathelicidin-related antimicrobial peptide in control mice was protective against development of skin papillomas. The cathelicidin-related antimicrobial peptide-mediated protection against papillomavirus skin infection and associated disease was mediated by modulation of the host’s immune system. These results indicate cathelicidins as important targets for future anti-papillomaviral compounds.
The murine PV, *Mus musculus papillomavirus 1* (MmuPV1), infects laboratory mice and induces outgrowth of skin papillomas in severely immunocompromised mice. In contrast, infection of immunocompetent mice is generally asymptomatic and transient, as PV infection and associated disease are controlled and cleared by the cellular immunity (13, 14).

The aim of the current study was to investigate the effects of the murine cathelicidin CRAMP against MmuPV1 skin infection and associated skin papillomatosis in genetically modified C57BL/6J mice deficient for CRAMP. In addition, potential antiviral mechanisms of CRAMP, such as disruption of particle integrity, inhibition of virus entry into and intracellular trafficking in infected keratinocytes, or modification of virus infection through modulation of immunity, were addressed.

**MATERIALS AND METHODS**

**Ethics statement**

The animal experiments were approved by the ethics committees of the Medical University of Vienna, Austria, and the Austrian Federal Ministry of Science and Research (BMWFU-66.009/0209-WF/V/3B/2016, BMWFU-66.009/0208-WF/V/3B/2016) and performed in full compliance with the institutional guidelines.

*Mus musculus papillomavirus 1 skin infection model*

Infectious MmuPV1 virions were purified from papillomatous tissue extracts derived from athymic nude mice, as described previously (15). Female C57BL/6J mice, aged 5–6 weeks, deficient for CRAMP in skin (Fig. S1), bone marrow, and neutrophil granules (11), (n = 16) were obtained from Charles River Laboratories Inc. (Wilmington, MA, USA) and calculated using the Comparative CT (ΔΔCT) method. The MmuPV1 copy numbers in the DNA samples were quantified by comparison with defined amounts of the MmuPV1 genome as standards after normalization to the housekeeping gene *ACTB* (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions.

**Virion preparation**

Infectious MmuPV1 virions were purified from papillomatous tissue extracts derived from athymic nude mice, as described previously (15). Female C57BL/6J mice, aged 5–6 weeks, deficient for CRAMP in skin (Fig. S1), bone marrow, and neutrophil granules (11), (n = 16) and WT controls (n = 16) were obtained from Charles River Laboratories Inc. (Wilmington, MA, USA). Experimental infection was performed with native MmuPV1 virions at 1×10^11 per site on the skin of the tails (16). Systemic immunosuppression was performed by subcutaneous administration of cyclosporine A (CsA) (Sandimmune®, Novartis, Basel, Switzerland) at a dose of 75 mg/kg body weight starting one week prior to infection 5 times per week for a total of 6 weeks (13). Mice were followed for the development of skin papillomas and at indicated time-points sera were obtained and skin tissues procured from the inoculation sites.

**Determination of MmuPV1-E1^E4 spliced transcripts, copy numbers and L1 capsid protein**

Crude skin tissue extracts were prepared, as described previously (15). Total RNA and genomic DNA were purified from the same skin tissue sample using TRI reagent (Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer’s instructions. MmuPV1-E1^E4 spliced transcripts, a marker for infectivity and viral transcription, and viral genome copy numbers were determined by real-time PCR, employing previously published primers and probes (15). MmuPV1-E1^E4 levels were normalized to the endogenous control ACTB (Thermo Fisher Scientific, Waltham, MA, USA) and calculated using the Comparative CT (ΔΔCT) method. The MmuPV1 copy numbers in the DNA samples were quantified by comparison with defined amounts of the MmuPV1 genome as standards after normalization to the housekeeping gene y-actin (15,17). Detection of the major capsid protein L1 in the skin tissue extracts was performed by Western blot, employing a polyclonal rabbit immune serum raised against MmuPV1-L1 at a dilution of 1:1,000 (15).

**Haematoxylin-eosin staining and immunohistochemistry**

Skin tissue sections were stained with haematoxylin-eosin or used for immunohistochemistry employing following primary antibodies: rabbit polyclonal CRAMP (diluted 1:2,000) (Innovagen AB, Lund, Sweden), rat-anti-mouse CD4 (diluted 1:10) (BD Biosciences, San Jose, CA, USA) and rat-anti-mouse CD8 (diluted 1:100) (BioLegend, San Diego, CA, USA). The MmuPV1 L1/L2-specific polyclonal immune serum was generated (Eurogentec, Seraing, Belgium) by immunization of a New Zealand White rabbit with 0.1 mg MmuPV1 L1/L2 PsVs in a 4-dose regimen at week 0–2–4–8. Serum was drawn 4 weeks after the final boost, affinity-purified and employed for immunohistochemistry diluted 1:4,000. All images were digitalized using an Aperio slide scanner (Leica Biosystems, Nussloch, Germany) and immunopositive cells per mm² skin tissue semi-quantitatively scored on anonymized samples using ImageJ.

**Single-molecule RNA in situ hybridization**

Detection of the MmuPV1 onconeogene E6/E7 mRNA was performed, employing the RNAscope® MusPV-E6-E7 probe (Advanced Cell Diagnostics, Newark, CA, USA) according to the manufacturer’s instructions. RNA integrity was verified with the endogenous control probe Mm-PPIB and background staining evaluated, employing the negative control probe specific for the bacterial DapB gene. Brightfield images were acquired using the Aperio slide scanner (Leica Biosystems, Nussloch, Germany).

**Peptide synthesis**

The synthetic murine CRAMP peptide was commercially obtained (Bachem, Bubendorf, Switzerland) and the scrambled control peptide (LPQKVELQLKIGPQEKKGFRGLKGEKQFIKI) containing the same amino acids in a randomly rearranged order, synthesized (JPT Peptide Technologies GmbH, Berlin, Germany).

**Peptide-enzyme-linked immunosorbent assay**

Peptide binding to native virions was assessed by peptide-enzyme-linked immunosorbent assay (ELISA) (18) and bound peptide-virion-complexes detected, employing the polyclonal rabbit immune serum recognizing MmuPV1-L1/L2.

**Transmission electron microscopy analyses**

To assess particle integrity 1×10^11 MmuPV1 virions were co-incubated with either the CRAMP or the control peptide at final concentrations ranging from 10–100 µg/ml for 24 h, adsorbed onto glow-discharged copper grids, fixed and negatively stained with 1% uranyl acetate for 20 min, washed in distilled water, air-dried and contrasted with uranyl acetate/lead citrate, prior to analyses.
at 120 kV employing a Libra 120 electron microscope (Carl Zeiss AG, Oberkochen, Germany). Acquisition of images was performed using a bottom stage digital camera, TRS (4 megapixel) and ImageSP professional software (Tröndle, Moorenweis, Germany).

Detection of *Mus musculus* papillomavirus 1-specific antibodies in mouse sera

MmuPV1-specific antibodies in the sera (dilution range 1:100 to 1:10,000) of CRAMP-KO and WT mice were detected by particle-envelope-linked immunooassay (particle-ELISA), employing native MmuPV1 virions as the antigen (20). MmuPV1-SEAP PsVs were obtained by co-transfection of 293TT cells with pMusheLL and a reporter plasmid encoding for secreted alkaline phosphatase (SEAP) (21). The presence of anti-MmuPV1 antibodies with neutralizing capacity in the mouse sera (dilution 1:100) was assessed, employing MmuPV1-SEAP PsVs (22). The IC<sub>50</sub> titre is defined as the highest serum dilution showing at least 50% reduction in SEAP signal compared with the negative controls, mouse pre-immune sera or in the absence of immune sera.

Statistical analyses

Statistical analyses were performed using GraphPad Prism 7. Differences between groups were analysed using Mann–Whitney test or 1-way analysis of variance (ANOVA) at 95% confidence interval (95% CI). A *p*-value < 0.05 was considered statistically significant. Data represent mean ± standard deviation (SD).

RESULTS

*Mus musculus* papillomavirus 1 infection causes skin papillomas in cyclosporine A-treated cathelicidin-related antimicrobial peptide-deficient C57BL/6J mice

C57BL/6J mice deficient for endogenous CRAMP consistently (100% at each time-point; 10/10 at day 23 and 5/5 at day 35 post-infection) developed cutaneous papillomas on their tails after MmuPV1 infection and systemic CsA immunosuppression (Fig. 1a). The papillomas were large, with mean lengths 16.2 ± 7.4 mm on day 35 post-infection. Histological analyses of tissue specimens additionally verified the presence of papillomas (Fig. 1b). Only a subset (40% at each time-point; 4/10 at day 23 and 2/5 at day 35 post-infection) of CsA-treated, MmuPV1-infected WT C57BL/6J controls, in contrast, developed skin papillomas (Fig. 1c) and the lesions were much smaller at 6.5 ± 9.1 mm.

To assess viral gene expression, skin tissues were harvested from the infection sites, regardless of whether visible lesions had evolved. In the tissues of CsA-treated, MmuPV1-infected CRAMP-KO mice abundant MmuPV1-E1<sup>E4</sup> spliced transcripts were present and the levels were significantly higher than in the tissues derived from infected WT mice. The viral copy numbers were also higher in CRAMP-KO mice, with levels ranging from 10<sup>6.7</sup> to 10<sup>7.2</sup> copies per mg of DNA. In contrast, the levels in WT mice were much lower, ranging from 10<sup>3.1</sup> to 10<sup>4.3</sup> copies per mg of DNA. These findings indicate that the clearance of the virus is more efficient in WT mice compared to CRAMP-KO mice.

Fig. 1. *Mus musculus* papillomavirus 1 (MmuPV1)-induced skin papillomas in cyclosporine A (CsA)-treated cathelicidin-related antimicrobial peptide (CRAMP)-knock out (KO) and wild-type (WT) mice. (a) CsA-treated, MmuPV1-infected CRAMP-deficient C57BL/6J mouse on day 35 post-infection. (b) Haematoxylin-eosin (HE) staining of a skin papilloma, showing hyperkeratosis, acanthosis, elongation of the rete ridges. Koilocytes in the epithelium are depicted in the insert. (c) CsA-treated, MmuPV1-infected WT C57BL/6J mouse on day 35 post-infection. (d) Levels of MmuPV1-E1<sup>E4</sup> spliced transcripts and (e) MmuPV1 viral copy numbers in infected tail skin tissues of CRAMP-KO and WT mice. MmuPV1-E6/E7 oncogene mRNA in (f) the papillomatous lesions of MmuPV1-infected CRAMP-KO mice and (g) infected skin of MmuPV1-infected WT controls. MmuPV1-L1/L2 capsid proteins in the epidermal skin layers of (h) MmuPV1-infected CRAMP-deficient and (i) MmuPV1-infected WT mice. (j) MmuPV1-L1 major capsid protein in crude skin tissue extracts derived from infected CRAMP-KO and WT mice. Purified MmuPV1 virions served as positive control.
from equally treated, infected WT controls ($p=0.0108$) (Fig. 1d). Similarly, the mean viral copy numbers in the infected tissues were approximately twice as high in the CRAMP-KO compared with the WT mice (Fig. 1e) and detection of these viral markers correlated well with the macroscopic appearances of the papillomas (not shown). The viral contribution was further confirmed by abundantly expressed MmuPV1-E6/E7 mRNA throughout the papillomas of the CRAMP-KO mice, demonstrating increased transcriptional activity of the viral oncogenes in the absence of endogenous CRAMP (Fig. 1f). In contrast, E6/E7 mRNA in the keratinocytes was sparse in the WT mice (Fig. 1g). Expression of the MmuPV1-L1/L2 capsid proteins in keratinocytes was restricted exclusively to tissues of CRAMP-KO mice, but not WT controls (Fig. 1h–j). The results demonstrate the role of endogenous CRAMP in protection against MmuPV1 skin infection and manifestation of virus-induced disease in vivo.

The immunosuppressive effect of CsA was a prerequisite for papilloma development, as lesional outgrowth was not observed macroscopically and histologically during the 8-week follow-up period in non-CsA-treated, MmuPV1-infected CRAMP-deficient (0%; 0/6) and WT C57BL/6J mice (0%; 0/6) (Fig. S21). Non-CsA-treated CRAMP-KO and WT mice also did not express MmuPV1-E1^E4, E6/E7 mRNA and L1/L2 proteins in infected tissues, and only very low viral copy numbers, which could be attributable to residual, partially cleared inoculum, were detectable (data not shown). These findings correspond with the absence of skin papillomas, possibly due to rapid elimination of viral infection in the C57BL/6J strain, which is regarded as resistant to MmuPV1-induced skin papillomatosis even under severe immunosuppressed conditions (13, 14).

**Synthetic cathelicidin-related antimicrobial peptide interacts directly with native Mus musculus papillomavirus 1 virions**

To determine whether CRAMP can interact directly with MmuPV1, binding of a synthetic CRAMP peptide to native virions was assessed by ELISA. Binding to the CRAMP peptide was specific, dose-dependent and higher ($p=0.0004$) compared with a scrambled control peptide (Fig. 2a), demonstrating that CRAMP could interact directly with native MmuPV1 particles.

**Cathelicidin-related antimicrobial peptide affects the integrity of native Mus musculus papillomavirus 1 virions**

To study the effect of CRAMP on particle integrity, native MmuPV1 virions were co-incubated with either the synthetic CRAMP or the scrambled control peptide, and the morphology of the viral particles was subsequently analysed by transmission electron microscopy. Exposure to the CRAMP peptide affected the structural integrity of the virions, as demonstrated by numerous broken particles with damaged membranes, particle conglomerates

Fig. 2. Cathelicidin-related antimicrobial peptide (CRAMP)-Mus musculus papillomavirus 1 (MmuPV1) virion interactions. (a) Binding of MmuPV1 virions to a synthetic CRAMP and a scrambled control peptide. One representative result out of 3 independent experiments is shown. (b) Electron micrographs showing damaged MmuPV1 virions, particle conglomerates and fragments in the presence of the synthetic CRAMP peptide and (c) intact particles in the presence of the scrambled control peptide (24-h exposure; final concentration 100 µg/ml). (d) Comparison of damaged virions after exposure to synthetic CRAMP or the control. (e) Thin-section electron micrographs showing native MmuPV1 virions attached to the keratinocyte surface, (f) bound in indentations of the cell membrane, (g) engulfed in intracellular vesicles in the presence of the synthetic CRAMP peptide (16-h time-point, final concentration 50 µg/ml). (h) Intravesicular virions in the keratinocyte in the presence of the control peptide (16-h time-point; final concentration 50 µg/ml).
and fragments (Fig. 2b). Incubation with the control, in contrast, had no effect on the particle structure and the virions remained relatively intact (Fig. 2c), similar to control grids, where MmuPV1 virions were analysed in the absence of any peptide (not shown). Quantification analyses revealed that co-incubation of CRAMP resulted in a higher, albeit statistically not significant, percentage of damaged viral particles compared with the control at 8.4% vs 4.4%, respectively ($p=0.1000$) (Fig. 2d). This effect was dose-dependent, as co-incubation with lower amounts of CRAMP resulted in lower numbers of defective particles (not shown).

**Cathelicidin-related antimicrobial peptide does not impair virus entry into keratinocytes and intracellular trafficking**

Next, the capability of CRAMP to interfere with virion-cell binding, virus entry and/or intracellular trafficking was assessed. Native MmuPV1 virions bound to the keratinocyte surface could readily be detected in the presence of the CRAMP peptide and were also found in slight indentations in the cell membranes, indicating virion uptake (Fig. 2e, f). Inside the keratinocytes, viruses were present in small vesicles up to 300 nm in length, that harboured one to several particles (Fig. 2g). This proved that binding, internalization and the initial steps of intracellular trafficking of MmuPV1 virions were not disturbed by CRAMP. Similarly, intracellular virus particles were also observed in the presence of equal amounts of control peptide (Fig. 2h).

**Cyclosporine A differently affects CD4+ and CD8+ T-cells in Mus musculus papillomavirus 1-infected skin of cathelicidin-related antimicrobial peptide-knock-out and wild-type mice**

Next, this study investigated the cellular infiltrate, particularly of CD4+ and CD8+ T-cells, which represent the antibody group capable of mediating epitopes in the papillomaviral capsid proteins, and fragments (Fig. 2b). Incubation with the control, in contrast, had no effect on the particle structure and the virions remained relatively intact (Fig. 2c), similar to control grids, where MmuPV1 virions were analysed in the absence of any peptide (not shown). Quantification analyses revealed that co-incubation of CRAMP resulted in a higher, albeit statistically not significant, percentage of damaged viral particles compared with the control at 8.4% vs 4.4%, respectively ($p=0.1000$) (Fig. 2d). This effect was dose-dependent, as co-incubation with lower amounts of CRAMP resulted in lower numbers of defective particles (not shown).

Cyclosporine A differently affects CD4+ and CD8+ T-cells in Mus musculus papillomavirus 1-infected skin of cathelicidin-related antimicrobial peptide-knock-out and wild-type mice

Next, this study investigated the cellular infiltrate, particularly of CD4+ and CD8+ T-cells, which represent the major players responsible for PV control and elimination, in the infected skin tissues. In non-CsA-treated, MmuPV1-infected mice numerous CD4+ and CD8+ T-cells were generally present in the skin tissues, particularly of the CRAMP-deficient mice (Fig. 3a, b). Quantification analyses revealed that the mean CD4+ and CD8+ T-cell numbers were 6.9-fold and 1.5-fold higher, respectively, in non-CsA-treated, MmuPV1-infected CRAMP-KO mice compared with WT controls. In the presence of CsA, however, papilloma-bearing MmuPV1-infected CRAMP-KO mice had 2.5-fold lower mean CD4+ T-cell numbers per mm² tissue compared with equally treated, MmuPV1-infected WT controls and 7.9-fold lower CD4+ numbers compared with non-CsA-treated, MmuPV1-infected littermates (Fig. 3a). CsA treatment, in contrast, did not reduce CD4+ counts in MmuPV1-infected WT mice, but resulted in 2.2-fold higher numbers compared with non-CsA-treated littermates. The mean CD8+ T-cell numbers were equally low in the skin tissues of CsA-treated, MmuPV1-infected CRAMP-KO and WT mice (Fig. 3b). CsA administration significantly reduced the mean CD8+ T-cell numbers by 30.6-fold in MmuPV1-infected CRAMP-KO mice compared with non-CsA-treated, MmuPV1-infected littermates. Similarly, CsA-treated, MmuPV1-infected WT mice had 37.4-fold lower mean CD8+ T-cell numbers compared with non-CsA-treated, infected littermates. This indicated that CsA-immunosuppression affected CD4+ rather than CD8+ T-cells in MmuPV1-infected mice deficient for endogenous CRAMP.

Cyclosporine A-treated cathelicidin-related antimicrobial peptide-knock-out mice fail to mount Mus musculus papillomavirus 1-specific antibodies with neutralizing capacity

Next, this study investigated the effects on the humoral immune response induced by endogenous CRAMP after MmuPV1 infection. Non-CsA-treated as well as CsA-treated CRAMP-KO and WT mice were able to mount a MmuPV1-specific antibody response after infection, as shown by virus particle-ELISA (Fig. S3). The functionality of the MmuPV1-specific antibodies, however, differed significantly between the individual experimental groups. Antibodies specific for neutralizing epitopes in the papillomaviral capsid proteins, which represent the antibody group capable of medi-
ating protection from viral infection (23), were readily
detectable in non-CsA-treated, MmuPV1-infected mice
(Fig. 3c) with significantly higher mean IC₅₀ titres in the
CRAMP-KO compared with the WT mice (p = 0.0005). Intriguingly, in the vast majority (80%; 8/10) of the
CsA-treated, MmuPV1-infected CRAMP-KO mice, neutralizing antibodies were undetectable, and in the
remaining 2 mice (20%) levels were low. In contrast, neu-
tralizing antibodies were present in sera of CsA-treated,
MmuPV1-infected WT mice at higher mean IC₅₀ titres
that were relatively comparable to the titres observed in
non-CsA-treated, MmuPV1-infected littermates. Unin-
fected mice lacked seroresponses (not shown).

DISCUSSION
This study demonstrates that endogenous CRAMP is pro-
tective against MmuPV1-induced skin papillomatosis in vivo, as CRAMP-deficient C57BL/6J mice consistently
developed large papillomas after systemic treatment with
CsA. Abundantly expressed viral markers in the papillo-
mas were indicative for active transcription and virion
production. The C57BL/6J strain was previously reported to
be resistant to MmuPV1-induced papillomatosis due to
immunological factors specific to this strain, in contrast
to mice on a different genetic background (13, 14). To
overcome the strain-specific resistance to virus-induced
skin papillomatosis, systemic CsA was administered to
lower T-cell activity and higher amounts of MmuPV1
virions (1×10¹² as opposed to 4.2×10¹⁰ per site in the
previous study (13)) were used for infection. The latter
would explain why some of the CsA-treated C57BL/6J
WT mice developed lesions, albeit small in size.

Previous reports have shown direct mechanisms how
cathelicidins, mostly human LL-37, exert antiviral ac-
activity against a variety of viruses (5–9, 24, 25). PVs lack a
viral envelope, hence, direct killing through permeabi-
ization of the envelope layer is ruled out as the operative
mechanism. While very modest effects of a synthetic
CRAMP peptide on virion integrity were demonstrated,
this mechanism alone seems insufficient to explain the
observed in vivo protection of WT mice against
MmuPV1-induced skin papillomatosis. Internalization of
virions into murine keratinocytes and intracellular
trafficking, including deposition into vesicles, were not
inhibited by the CRAMP peptide, although we have not
investigated the fate of the viral particles, as an impact
of the released peptide on the transition of the virus from
the endosome to the nucleus seems unlikely.

In general, cytotoxic CD8⁺ T-cell responses are re-
ponsible for the control and clearance of many viral
infections and for the elimination of virus-infected cells,
whereas certain CD4⁺ T-cells modulate cytotoxic T-cell
activation via production of antiviral cytokines and
release of cytotoxic molecules. In addition, protective
antiviral cytotoxic CD4⁺ T-cell responses have been ob-
served during a multitude of virus infections, including
herpes-, cytomegal-, and lymphochoriomeningitis viru-
ses (26, 27), as well as in MmuPV1-infected C57BL/6J
mice (13). The current study demonstrated strong CD4⁺
and CD8⁺ T-lymphocytic infiltration in the skin of
CRAMP-expressing WT and CRAMP-deficient KO mice
after MmuPV1 infection, which presumably prevented
virally-induced papilloma outgrowth. In the presence of
systemic CsA, which inhibits T-lymphocyte activation by
targeting calcineurin and the mitogen-activated protein
kinases JNK and p38 within the interleukin 2 pathway
(28), differential T- and B-cell responses were observed
in the absence or presence of CRAMP.

In CsA-treated CRAMP-expressing WT mice CD8⁺
T-cells were reduced, whereas CD4⁺ T-cells were up-
regulated. Given the possible cytotoxic capacity of the
CD4⁺ T-cells, this T-cell subset may suffice to control
viral infection and prevent lesional outgrowth, even in
the absence of CD8⁺ T-cells. In this line, the CsA-treated
WT mice which had fewer CD4⁺ T-cells were the ones
that developed small papillomas. In the infected skin
tissues of CRAMP-deficient mice, CsA significantly
reduced both CD4⁺ and CD8⁺ T-cells. It is conceivable
that, in the absence of endogenous CRAMP, the remain-
ing CD4⁺ T-cells might not be sufficient in numbers to
protect against papillomatosis, for instance in exerting
the required cytotoxic effector functions for viral elimina-
tion or in providing sufficient help to the CD8⁺ T-cells.
Alternatively, T-cell function might be altered in the
CRAMP-KO mice in response to CsA, thus impairing ef-
cient suppression of viral infection and papillomatosis.

Next to the cytotoxic activity of T-cells, neutralizing
antibodies are important in viral defence, in particular
during the state prior to viral entry into the target cell.
The current study showed striking differences in the
B-cell responses to MmuPV1 infection between WT and
CRAMP-KO mice with the effect of CsA immunomodu-
lation. In general, PV-specific antibodies induced either
after vaccination or after infection are not active against
established disease, but prevent new infection. While we
do not believe that the neutralizing antibodies generated
in this study in the mice after MmuPV1 infection play
a decisive role in protecting against virus infection and
disease, due to the latency after which antibodies are
generated, the complete absence of neutralizing antibo-
dies in the CsA-treated CRAMP-KO mice was striking,
and suggested that the absence of endogenous CRAMP
might impair T-cell mediated B-cell maturation and
function in response to CsA. Another possible explana-
tion is that antibody-dependent cytotoxicity is impaired
in the CsA-treated CRAMP-KO mice. In this scenario,
the lack of (functionally active) antibodies would prevent
recognition and subsequent elimination of virus-infected
cells by cytotoxic T-cells. The presence of MmuPV1-
specific antibodies in both CsA-treated KO and WT mice
argues against antibodies as the effective key players in
preventing MmuPV1-induced papillomatosis, but rather points to the presence of cytotoxic CD4+ T-cells and, indirectly, to a role for CRAMP in T-cell regulation and/or activation. We cannot exclude that other cellular players might also be involved in in vivo protection of CRAMP against papillomaviral infection, such as skin-infiltrating plasmacytoid dendritic cells and/or Langerhans cells. In the absence of CRAMP, antigen-presentation may be impaired in the CRAMP-KO mice, especially during a subdued immunological state; for example, by CsA.

In conclusion, this study showed that protection against MmuPV1-induced skin papillomatosis in vivo is mediated by CRAMP. Absence of CRAMP, together with CsA immunosuppression, affects both cytotoxic T-cell activity and specific antibody production, indicating cathelicidins as important targets for future anti-papillomaviral compounds.

**ACKNOWLEDGEMENTS**

This research was supported by the Austrian Science Fund (FWF P29619-B30) and the Medical-Scientific Fund of the Mayor of Vienna (BGM 17019). Electron microscopy sample preparation and analyses of keratinocytes were performed at the Core Facility Cell Imaging and Ultrastructure Research, University of Vienna – member of the Vienna Life Science Instruments (VLSI). The authors thank Roland Tresky, Ruth Dingelmaier-Hovorka, and Ulrike Mann for their excellent technical assistance, Wolfgang P. Weninger, MD, for helpful discussions and John T. Schiller, PhD, for valuable suggestions and critical reading of the manuscript. S1 mouse keratinocytes and 293TT cells were kindly provided by Weninger, MD, for helpful discussions and John T. Schiller, PhD, and Patricia M. Day, PhD, National Institutes of Health, National Cancer Institute, Bethesda, MD, USA.

The authors have no conflicts of interest to declare.

**REFERENCES**

1. Afshar M, Gallo RL. Innate immune defense system of the skin. Vet Dermatol 2013; 24: 32–8.e8–9.
2. Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Meruzzi L, et al. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 1997; 272: 13088–13093.
3. Dorschner RA, Pestonjamasp VK, Tamakwala S, Ohtake T, Rudisill J, Nizet V, et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A streptococcus. J Invest Dermatol 2001; 117: 91–97.
4. Conner K, Kern K, Rudisill J, O’Grady T, Gallo RL. The anti-microbial peptide LL-37 is expressed by keratinocytes in condyloma acuminatum and verruca vulgaris. J Am Acad Dermatol 2002; 47: 347–350.
5. Crack LR, Jones L, Malavige GN, Patel V, Ogg GS. Human antimicrobial peptides LL-37 and human β-defensin-2 reduce viral replication in keratinocytes infected with varicella zoster virus. Clin Exp Dermatol 2012; 37: 534–543.
6. Currie SM, Gwyer Findlay E, McFarlane AJ, Pitch PM, Böttcher B, Colegrave N, et al. Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans. J Immunol 2016; 196: 2699–2710.
7. Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C, et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006; 117: 836–841.
8. Howell MD, Jones JF, Kisch KO, Streib JE, Gallo RL, Leung DY. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol 2004; 172: 1763–1967.
9. Tripathi S, Tectle T, Verma A, Crouch E, White M, Hartshorn KL. The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. J Gen Virol 2013; 94: 40–49.
10. Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, et al. Antiviral activity and increased host defense against influenza virus elicited by the human cathelicidin LL-37. PLoS One 2011; 6: e25353.
11. Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414: 454–457.
12. Buck CB, Day PM, Thompson CD, Lukbowski J, Lu W, Lowy DR, et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 2006; 103: 1516–1521.
13. Handsuraya A, Day PM, Thompson CD, Bonelli M, Lowy DR, Schiller JT. Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1. PLoS Pathog 2014; 10: e1004314.
14. Uheroi A, Lambert PF. Rodent papillomaviruses. Viruses 2017; 9: 362.
15. Handsuraya A, Day PM, Thompson CD, Buck CB, Pang Y-YS, Lowy DR, et al. Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization. J Virol 2013; 87: 13214–13225.
16. Handsuraya A, Day PM, Thompson CD, Buck CB, Kwak K, Roden RBS, et al. Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology 2012; 433: 385–394.
17. Day PM, Lowy DR, Schiller JT. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 2003; 307: 1–11.
18. Zamora E, Handsuraya A, Shafti-Keramat S, Borchelt D, Rudow G, Conant K, et al. Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J Immunol 2006; 177: 2662–2670.
19. Shafti-Keramat S, Handsuraya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirmbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 2003; 77: 13125–13135.
20. Krbnauber R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994; 86: 494–499.
21. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J Virol 2004; 78: 751–757.
22. Pastrana DV, Buck CB, Pang Y-YS, Thompson CD, Castle PE, FitzGerald PC, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321: 205–216.
23. Day PM, Gambhir R, Roden RBS, Lowy DR, Schiller JT. Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. J Virol 2008; 82: 4638–4646.
24. Currie SM, Findlay EG, McHugh BJ, Mackellar A, Man T, Macmillan D, et al. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One 2013; 8: e73659.
25. Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE, et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006; 24: 341–348.
26. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375: 411–415.
27. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. Nature Rev Immunol 2012; 12: 136–148.
28. Barbarino JM, Staatze CE, Venkatakraman R, Klein TE, Altman RB. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 2013; 23: 563–585.